James M Ford

List of Publications by Year in Descending Order

184 papers	11,316 citations	59 h-index	104 g-index
208 ext. papers	13,168 ext. citations	6.7 avg, IF	5.99 L-index

#	Paper	IF	Citations
184	Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes.. *Cancers*, **2022**, 14,	6.6	1
183	Phase II Study of Taselisib in -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.. *JCO Precision Oncology*, **2022**, 6, e2100424	3.6	1
182	MITI minimum information guidelines for highly multiplexed tissue images.. *Nature Methods*, **2022**, 19, 262-267	21.6	2
181	Somatic tumor testing implications for Lynch syndrome germline genetic testing.. *Cancer Genetics*, **2022**, 264-265, 16-22	2.3	0
180	Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. *Cancers*, **2022**, 14, 2716	6.6	1
179	A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer.. *Journal of Clinical Oncology*, **2021**, 39, TPS1109-TPS1109	2.2	2
178	A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma. *DNA Repair*, **2021**, 97, 103022	4.3	3
177	Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT basket trial.. *Journal of Clinical Oncology*, **2021**, 39, 320-320	2.2	7
176	Subtle endoscopic manifestations of diffuse signet cell gastric adenocarcinoma in patients with CDH1 mutations. *Gastrointestinal Endoscopy*, **2021**, 94, 1146-1147	5.2	
175	Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer. *Cancer Medicine*, **2021**, 10, 1012-1017	4.8	5
174	Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. *Cancer*, **2021**, 127, 1275-1285	6.4	7
173	Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer. *Scientific Reports*, **2020**, 10, 5009	4.9	1
172	Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel. *Journal of Molecular Diagnostics*, **2020**, 22, 544-554	5.1	6
171	Germline Testing for Patients With Mutations on Somatic Tumor Testing. *JNCI Cancer Spectrum*, **2020**, 4, pkz095	4.6	7
170	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. *Cell*, **2020**, 181, 236-249	56.2	140
169	Gastric Cancer Registry: A comprehensive patient-reported resource for multidisciplinary and translational genomic approaches to gastric cancer.. *Journal of Clinical Oncology*, **2020**, 38, 432-432	2.2	
168	Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. *Journal of Clinical and Translational Hepatology*, **2020**, 8, 377-384	5.2	0

167	Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.. *Journal of Clinical Oncology*, **2020**, 38, 1549-1549	2.2	
166	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. *Clinical Cancer Research*, **2020**, 26, 2704-2710	12.9	12
165	Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford. *JNCI Cancer Spectrum*, **2020**, 4, pkaa054	4.6	4
164	Hereditary diffuse gastric cancer: updated clinical practice guidelines. *Lancet Oncology, The*, **2020**, 21, e386-e397	21.7	95
163	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. *JCO Precision Oncology*, **2020**, 4,	3.6	2
162	DNA Damage Response Pathways and Cancer **2020**, 154-164.e4		4
161	High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients. *Clinical Cancer Research*, **2019**, 25, 5301-5314	12.9	5
160	Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations. *BMC Medical Genomics*, **2019**, 12, 84	3.7	12
159	Chromatin Remodeling in Response to BRCA2-Crisis. *Cell Reports*, **2019**, 28, 2182-2193.e6	10.6	1
158	Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. *JCO Precision Oncology*, **2019**, 3,	3.6	7
157	Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue. *DNA Repair*, **2019**, 83, 102644	4.3	9
156	HAT1 Coordinates Histone Production and Acetylation via H4 Promoter Binding. *Molecular Cell*, **2019**, 75, 711-724.e5	17.6	24
155	Genomics in medicine: a novel elective rotation for internal medicine residents. *Postgraduate Medical Journal*, **2019**, 95, 569-572	2	3
154	Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containingBRCA1andBRCA2mutations **2019**,		6
153	Preventive surgery after multiplex genetic panel testing (MGPT).. *Journal of Clinical Oncology*, **2019**, 37, 1525-1525	2.2	1
152	Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.. *Journal of Clinical Oncology*, **2019**, 37, 3006-3006	2.2	23
151	JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti-PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.. *Journal of Clinical Oncology*, **2019**, 37, TPS2660-TPS2660	2.2	5
150	Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers.. *Journal of Clinical Oncology*, **2019**, 37, 215-215	2.2	3

149	Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. *Breast Cancer Research and Treatment*, **2018**, 168, 625-630	4.4	55
148	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. *Clinical Cancer Research*, **2018**, 24, 2851-2858	12.9	38
147	Long-read genome sequencing identifies causal structural variation in a Mendelian disease. *Genetics in Medicine*, **2018**, 20, 159-163	8.1	127
146	From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. *Value in Health*, **2018**, 21, 1062-1068	3.3	12
145	NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2018**, 16, 939-949	7.3	78
144	Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions. *Health Affairs*, **2018**, 37, 751-756	7	13
143	Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs. *Oncotarget*, **2018**, 9, 12316-12322	3.3	25
142	Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling.. *Journal of Clinical Oncology*, **2018**, 36, 1582-1582	2.2	
141	Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling.. *Journal of Clinical Oncology*, **2018**, 36, 1581-1581	2.2	
140	Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. *Genetics in Medicine*, **2018**, 20, 234-239	8.1	72
139	Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study.. *JCO Precision Oncology*, **2018**, 2, 1-12	3.6	2
138	Rapid detection of recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. *Oncotarget*, **2018**, 9, 7832-7843	3.3	6
137	Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies.. *JCO Precision Oncology*, **2018**, 2, 1-4	3.6	0
136	Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?. *JCO Precision Oncology*, **2018**, 2, 1-10	3.6	2
135	Patient communication of cancer genetic test results in a diverse population. *Translational Behavioral Medicine*, **2018**, 8, 85-94	3.2	21
134	Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst. *Journal of Physical Education and Sports Management*, **2018**, 4,	2.8	5
133	A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs. *Journal of Oncology Practice*, **2017**, 13, e108-e119	3.1	57
132	Tumor Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. *Clinical Cancer Research*, **2017**, 23, 3365-3370	12.9	39

131	IDH2 Mutation in a Patient with Metastatic Colon Cancer. *New England Journal of Medicine*, **2017**, 376, 1991-2	59.2	10
130	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. *Npj Breast Cancer*, **2017**, 3, 22	7.8	78
129	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 1465-1475	7.3	81
128	Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 13792-13797	11.5	61
127	Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases. *Genome Medicine*, **2017**, 9, 57	14.4	42
126	Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. *JCO Precision Oncology*, **2017**, 1,	3.6	3
125	Pathogenic germline mutations in emerging cancer genes: What happens after panel testing?. *Journal of Clinical Oncology*, **2017**, 35, 1528-1528	2.2	1
124	Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers. *Oncotarget*, **2017**, 8, 26344-26355	3.3	14
123	Expanded yield of multiplex panel testing in fully accrued prospective trial.. *Journal of Clinical Oncology*, **2017**, 35, 1525-1525	2.2	
122	Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.. *Journal of Clinical Oncology*, **2017**, 35, 1523-1523	2.2	
121	Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.. *Journal of Clinical Oncology*, **2017**, 35, 1576-1576	2.2	
120	Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. *Journal of Medical Genetics*, **2016**, 53, 15-23	5.8	57
119	A Chimeric ATP-Linked Nucleotide Enables Luminescence Signaling of Damage Surveillance by MTH1, a Cancer Target. *Journal of the American Chemical Society*, **2016**, 138, 9005-8	16.4	11
118	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 3764-73	12.9	438
117	Optimizing Genotype Matched Clinical Trial (GMCT) accrual in a community oncology program (COP).. *Journal of Clinical Oncology*, **2016**, 34, e18036-e18036	2.2	
116	Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer (TNBC).. *Journal of Clinical Oncology*, **2016**, 34, 1010-1010	2.2	
115	Yield of multiplex panel testing compared to expert opinion and validated prediction models.. *Journal of Clinical Oncology*, **2016**, 34, 1509-1509	2.2	
114	Genomic profiling and targeted therapy in cholangiocarcinoma to yield positive clinical outcomes.. *Journal of Clinical Oncology*, **2016**, 34, e23162-e23162	2.2	

113	DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. *Cancer Treatment Reviews*, **2016**, 44, 1-9	14.4	10
112	Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel. *Journal of Molecular Diagnostics*, **2016**, 18, 580-94	5.1	23
111	Genetic predisposition to gastric cancer. *Seminars in Oncology*, **2016**, 43, 554-559	5.5	47
110	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. *Journal of Medical Genetics*, **2015**, 52, 361-74	5.8	385
109	A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. *Journal of Molecular Diagnostics*, **2015**, 17, 533-44	5.1	133
108	American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome. *Gastroenterology*, **2015**, 149, 783-813.e20	13.3	35
107	Parent decision-making around the genetic testing of children for germline TP53 mutations. *Cancer* , **2015**, 121, 286-93	6.4	35
106	Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. *Cancer Discovery*, **2015**, 5, 488-505	24.4	76
105	Multigene Panel Testing in Oncology Practice: How Should We Respond?. *JAMA Oncology*, **2015**, 1, 277-8	13.4	53
104	BRCA1: Beyond double-strand break repair. *DNA Repair*, **2015**, 32, 165-171	4.3	11
103	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. *Journal of Clinical Oncology*, **2015**, 33, 1895-901	2.2	166
102	Metastatic lobular breast carcinoma mimicking primary signet ring adenocarcinoma in a patient with a suspected CDH1 mutation. *Journal of Clinical Oncology*, **2015**, 33, e19-21	2.2	13
101	Discovery and functional characterization of a neomorphic PTEN mutation. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 13976-81	11.5	31
100	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. *JAMA Oncology*, **2015**, 1, 943-51	13.4	226
99	The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. *Cancer Genetics*, **2015**, 208, 448-54	2.3	33
98	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. *Journal of Clinical Oncology*, **2015**, 33, 3660-7	2.2	360
97	Colorectal Cancer Screening, Version 1.2015. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 959-68; quiz 968	7.3	61
96	Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. *Current Opinion in Obstetrics and Gynecology*, **2015**, 27, 23-33	2.4	28

95	Multiple-Gene Panels and the Future of Genetic Testing. *Current Breast Cancer Reports*, **2015**, 7, 98-104	0.8	1
94	BRCA1: a movement toward cancer prevention. *Molecular and Cellular Oncology*, **2015**, 2, e979685	1.2	0
93	Abstract P5-04-03: Deconvoluting immune cell populations using in silico flow cytometry with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC **2015**,		3
92	Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer.. *Journal of Clinical Oncology*, **2015**, 33, 1018-1018	2.2	1
91	Clinical impact of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment.. *Journal of Clinical Oncology*, **2015**, 33, 1513-1513	2.2	1
90	Precision medicine to improve survival without increasing costs in advanced cancer patients.. *Journal of Clinical Oncology*, **2015**, 33, e17641-e17641	2.2	4
89	Pretreatment lab values to predict overall survival in patients with primary unresectable pancreatic adenocarcinoma treated with SBRT.. *Journal of Clinical Oncology*, **2015**, 33, 433-433	2.2	
88	Design and implementation of an informatics infrastructure for actionable precision oncology.. *Journal of Clinical Oncology*, **2015**, 33, e17521-e17521	2.2	
87	Association of tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based therapy in breast cancer (BC) with therapy resistance.. *Journal of Clinical Oncology*, **2015**, 33, 1094-1094	2.2	
86	Implementation of a precision cancer program in an integrated health care system.. *Journal of Clinical Oncology*, **2015**, 33, e17647-e17647	2.2	1
85	Molecular profiling (MP) programs to increase access to targeted therapies in a rural setting.. *Journal of Clinical Oncology*, **2015**, 33, e17576-e17576	2.2	
84	Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells. *Cancer Letters*, **2014**, 343, 217-23	9.9	20
83	Clinical interpretation and implications of whole-genome sequencing. *JAMA - Journal of the American Medical Association*, **2014**, 311, 1035-45	27.4	333
82	The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype. *European Journal of Human Genetics*, **2014**, 22, 617-24	5.3	30
81	Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. *Genome Biology*, **2014**, 15, 428	18.3	85
80	American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. *Journal of Clinical Oncology*, **2014**, 32, 833-40	2.2	164
79	Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. *Journal of Clinical Oncology*, **2014**, 32, 2001-9	2.2	363
78	Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair. *Cancer Research*, **2014**, 74, 6205-15	10.1	18

77	Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.. *Journal of Clinical Oncology*, **2014**, 32, 1000-1000	2.2	17
76	A quality outcomes analysis following treatment with personalized genomic cancer medicine.. *Journal of Clinical Oncology*, **2014**, 32, 12-12	2.2	1
75	A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma.. *Journal of Clinical Oncology*, **2014**, 32, 115-115	2.2	1
74	DNA Damage Response Pathways and Cancer **2014**, 142-153.e3		1
73	A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 512-7	7.3	2
72	Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. *PLoS ONE*, **2013**, 8, e54014	3.7	148
71	Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. *DNA Repair* , **2012**, 11, 522-4	4.3	13
70	Is breast cancer a part of Lynch syndrome?. *Breast Cancer Research*, **2012**, 14, 110	8.3	8
69	Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. *Breast Cancer Research and Treatment*, **2012**, 136, 931-3	4.4	13
68	Lupus antibody tops cancer cells. *Science Translational Medicine*, **2012**, 4, 157fs38	17.5	
67	Genetic Polymorphisms as Predictors of Breast Cancer Risk. *Current Breast Cancer Reports*, **2012**, 4, 232-239	2.9	1
66	Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort. *World Journal of Surgery*, **2012**, 36, 702-13	3.3	17
65	Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. *Breast Cancer Research and Treatment*, **2012**, 133, 1125-30	4.4	120
64	Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis. *PLoS ONE*, **2012**, 7, e43994	3.7	74
63	Genetic testing by cancer site: stomach. *Cancer Journal (Sudbury, Mass)*, **2012**, 18, 355-63	2.2	55
62	Identification of a Functional In Vivo p53 Response Element in the Coding Sequence of the Xeroderma Pigmentosum Group C Gene. *Genes and Cancer*, **2012**, 3, 131-40	2.9	11
61	HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. *Applied Immunohistochemistry and Molecular Morphology*, **2012**, 20, 13-24	1.9	97
60	Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR. *Translational Medicine (Sunnyvale, Calif)*, **2012** , 2,		24

59	Seventh edition (2010) of gastric adenocarcinoma AJCC staging system: Is there room for improvement?. *Journal of Clinical Oncology*, **2012**, 30, 77-77	2.2	
58	Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. *Annals of Internal Medicine*, **2011**, 155, 69-79	8	248
57	A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer. *Familial Cancer*, **2011**, 10, 233-7	3	19
56	Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. *BMC Pharmacology*, **2011**, 11, 7		33
55	A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. *Annals of Surgical Oncology*, **2011**, 18, 2594-8	3.1	73
54	Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, 181-8	4	188
53	A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male. *Rare Tumors*, **2011**, 3, e45	1.1	8
52	Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. *Cancer Research*, **2010**, 70, 7970-80	10.1	128
51	Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 605-13	4	71
50	Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. *Cancer Research*, **2010**, 70, 512-9	10.1	201
49	Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. *Clinical Cancer Research*, **2010**, 16, 4702-10	12.9	120
48	NCCN clinical practice guidelines in oncology. Colorectal cancer screening. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2010**, 8, 8-61	7.3	145
47	PARP Inhibitors for the Treatment and Prevention of Breast Cancer. *Current Breast Cancer Reports*, **2010**, 2, 190-197	0.8	22
46	18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2010**, 77, 1420-5	4	101
45	PARP inhibitors in breast cancer. *Clinical Advances in Hematology and Oncology*, **2010**, 8, 629-35	0.6	25
44	Second primary breast cancer occurrence according to hormone receptor status. *Journal of the National Cancer Institute*, **2009**, 101, 1058-65	9.7	90
43	Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. *Cancer Research*, **2009**, 69, 3589-96	10.1	114
42	The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair. *DNA Repair*, **2009**, 8, 795-802	4.3	17

41	Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. *Cancer Genetics and Cytogenetics*, **2009**, 193, 9-18		30
40	Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. *Cancer*, **2009**, 115, 665-72	6.4	291
39	Performance of BRCA1/2 mutation prediction models in Asian Americans. *Journal of Clinical Oncology*, **2008**, 26, 4752-8	2.2	52
38	Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. *American Journal of Surgical Pathology*, **2008**, 32, 1029-37	6.7	78
37	Identifying and Preventing High-risk Gastric Cancer Individuals With CDH1 Mutations. *Annals of Surgery*, **2008**, 247, 715-716	7.8	
36	Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. *American Journal of Surgical Pathology*, **2008**, 32, 799-809	6.7	112
35	Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. *Familial Cancer*, **2008**, 7, 179-86	3	54
34	Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family. *Pediatric Blood and Cancer*, **2008**, 50, 914-6	3	8
33	Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. *Cancer*, **2008**, 113, 1850-6	6.4	65
32	Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. *International Journal of Radiation Oncology Biology Physics*, **2008**, 72, 678-86	4	257
31	DNA Damage Response Pathways and Cancer **2008**, 139-152		3
30	A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. *Cancer Genetics and Cytogenetics*, **2007**, 179, 89-92		10
29	HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 19482-7	11.5	189
28	Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. *JAMA - Journal of the American Medical Association*, **2007**, 297, 2360-72	27.4	324
27	Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. *Molecular Pharmacology*, **2007**, 71, 1233-40	4.3	85
26	CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. *Annals of Surgery*, **2007**, 245, 873-9	7.8	133
25	Molecular Inversion Probes (MIPs) Identify Novel Areas of Allelic Imbalance in Childhood Leukemia.. *Blood*, **2007**, 110, 1438-1438	2.2	
24	Predicting and preventing hereditary colorectal cancer. *JAMA - Journal of the American Medical Association*, **2006**, 296, 1521-3	27.4	16

23	Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. *Clinical Cancer Research*, **2006**, 12, 3389-93	12.9	35
22	Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. *Cancer Research*, **2006**, 66, 7910-9	10.1	29
21	A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. *Molecular Cell*, **2006**, 22, 489-99	17.6	49
20	Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling. *EMBO Journal*, **2006**, 25, 2605-14	13	84
19	Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. *International Journal of Radiation Oncology Biology Physics*, **2005**, 63, 320-3	4	267
18	Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. *Health Expectations*, **2005**, 8, 221-33	3.7	17
17	Regulation of DNA damage recognition and nucleotide excision repair: another role for p53. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2005**, 577, 195-202	3.3	86
16	Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. *Clinical Cancer Research*, **2005**, 11, 5401-9	12.9	168
15	BRCA1 and p53: compensatory roles in DNA repair. *Journal of Molecular Medicine*, **2003**, 81, 700-7	5.5	37
14	Functional characterization of global genomic DNA repair and its implications for cancer. *Mutation Research - Reviews in Mutation Research*, **2003**, 544, 107-14	7	95
13	In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product. *Journal of Biological Chemistry*, **2003**, 278, 46906-10	5.4	192
12	The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. *DNA Repair*, **2003**, 2, 819-26	4.3	74
11	p53 and regulation of DNA damage recognition during nucleotide excision repair. *DNA Repair*, **2003** , 2, 947-54	4.3	133
10	p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. *Carcinogenesis*, **2003**, 24, 843-50	4.6	62
9	DNA Damage, Repair, and Diseases. *Journal of Biomedicine and Biotechnology*, **2002**, 2, 45		11
8	BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. *Nature Genetics*, **2002**, 32, 180-4	36.3	195
7	p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 12985-90	11.5	251
6	The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts. *Journal of Biological Chemistry*, **2001**, 276, 25813-22	5.4	53

5	Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells. *Molecular Carcinogenesis*, **2000**, 29, 17-24	5	43
4	p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. *Molecular and Cellular Biology*, **2000**, 20, 3705-14	4.8	369
3	Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. *Molecular Cell*, **2000**, 5, 737-44	17.6	275
2	Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. *Journal of Biological Chemistry*, **1997**, 272, 28073-80	5.4	259
1	Single-cell analyses reveal a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer		1